Tagged with Alzheimer's

France Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important…

France Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why France Alzheimer together with other learned societies filed a case with the State Council against the French Minister of Health & Solidarity.   Alzheimer’s scares. Why? Because it is…

Singapore Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s relocation to Asia, and the upcoming rollout of a global Phase III clinical trial for its innovative new Alzheimer’s drug.   As a small, innovative biotech company, we are looking…

UK One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical research; more than both the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). Simon Gillespie, chief…

Biogen After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field where research has met relentless challenges and a series of drug candidates have been unsuccessful. Indeed, the failure rate for Alzheimer’s drugs has been 99.6 percent over the…

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

UK Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia research, the strengths and weaknesses of the UK’s medical research environment, and the potential effects of Brexit.   In all…

UK Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia research, care and diagnosis; and the enduring importance of international collaboration.   In the UK, when people want to help…

Austria Karsten Schlemm MD, CEO of Merz Pharma Austria, a leading international German based aesthetic company, provides an in-depth look into the company´s transformation from pharmaceuticals to the aesthetics sector as well as their exciting new offerings for cosmetic patients. He also gives an insight into the growing weight and Austrians’…

Slovakia Biogen Slovakia’s Country Director on being an innovative global biotech in Slovakia, market access in the country, and the company’s commitment to improving the lives of patients through MS, Alzheimer’s and rare disease treatments. Ms. Strapkova Boydova, you have been Country Director of Biogen Slovakia since its inception in 2006.…